Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02468687
Registration number
NCT02468687
Ethics application status
Date submitted
2/06/2015
Date registered
11/06/2015
Date last updated
5/05/2022
Titles & IDs
Public title
NMP in Relapsed / Refractory Myeloma
Query!
Scientific title
A Phase I, Open Label Dose Escalation Trial of Orally Administered N-methyl-pyrrolidone (NMP) in Patients With Relapsed or Refractory Myeloma
Query!
Secondary ID [1]
0
0
HREC/14/MH/159
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - N-methyl-pyrrolidone
Other: N-methyl-pyrrolidone - NMP dose escalation in accelerated phase and standard phase
Treatment: Drugs: N-methyl-pyrrolidone
NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse events to establish the Maximum Tolerated Dose (MTD)
Query!
Assessment method [1]
0
0
Each patient will be monitored for adverse events during the first cycle of NMP treatment (28 days) to establish the maximum tolerated dose
Query!
Timepoint [1]
0
0
28 days
Query!
Secondary outcome [1]
0
0
Optimum biological dose (OBD)
Query!
Assessment method [1]
0
0
The maximum changes in correlative biomarkers will be tested at the specific time-points. Descriptive statistics will be used to analyse data from correlative studies and summarized in graphical or tabular formats as appropriate.
Query!
Timepoint [1]
0
0
6 months
Query!
Secondary outcome [2]
0
0
Safety of the repeated dosing of NMP by oral administration - possible toxicities
Query!
Assessment method [2]
0
0
To assess safety, the numbers and rates (with confidence intervals) of patients experiencing any haematological and non-haematological and specific grade 3+ adverse events experienced at each given dose level and schedule of NMP will be calculated, over the full treatment period and by cycle
Query!
Timepoint [2]
0
0
6 months
Query!
Secondary outcome [3]
0
0
Pharmacokinetic properties of NMP after oral administration
Query!
Assessment method [3]
0
0
Pick plasma concentrations (Cmax) of NMP
Query!
Timepoint [3]
0
0
Predose,0.5,1,2,4,8, 24 hours post dose
Query!
Secondary outcome [4]
0
0
Response rate measured using IMWG criteria
Query!
Assessment method [4]
0
0
Patients will be evaluated for response after every 28 day cycle for the first 6 cycles of treatment and thereafter every 2 months in follow up using the IMWG criteria for multiple myeloma.
Query!
Timepoint [4]
0
0
6 months up to 2 years
Query!
Secondary outcome [5]
0
0
Time to progression from start of treatment
Query!
Assessment method [5]
0
0
Patients will be assessed for disease progression weekly in Cycle 1, then monthly on D1 of each cycle during treatment for the first 6 months and then monthly until disease progression, next anti-cancer treatment or death. Time to progression from start of treatment will be estimated using Kaplan Meier survival curves.
Query!
Timepoint [5]
0
0
up to 3.5 years
Query!
Eligibility
Key inclusion criteria
1. Histologically confirmed diagnosis of plasma cell myeloma defined by WHO 2008 criteria
2. Measurable disease as defined by at least one of:
* serum M protein =5g/L
* urine M protein = 200mg/24hrs
* involved serum free light chain = 100mg/L
* measurable (by imaging at the discretion of the investigator) soft tissue plasmacytoma
3. Relapsed, refractory or intolerant of both bortezomib and lenalidomide
Definitions:
* refractory at least 4 weeks of therapy administered, with less than a partial response by IMWG criteria
* relapsed from previous response (PR or greater) to therapy, with subsequent disease progression as defined as development of bone marrow dysfunction (fall in Hb of 20g/L or platelet count <100 x 109/L) due to increased bone marrow plasmacytosis
* OR new lytic bone lesions
* OR increase in serum M protein of 5g/L
* OR absolute increase of involved serum free light chain of >250mg/L
* intolerant: grade 2 or higher toxicity unresponsive to dose adjustment 4. Prior autologous stem cell transplant, unless ineligible for transplant by the discretion of the investigator.
5. age =18 years 6. ECOG performance status <2 7. The following values within 7 days of commencing NMP (blood transfusions prior to study entry are permitted)
* Haemoglobin >80g/L
* Absolute neutrophil count >1.0 x 109/L
* Platelet count = 25 x 109/L
* Creatinine clearance >30ml/min (by Cockcroft/Gault)
* Bilirubin = 3x upper limit of normal (ULN)
* ALT = 3 x ULN
* Left ventricular ejection fraction (LVEF) =45% (by gated cardiac blood pool scan or echocardiography) 9. Life expectancy > 3 months 10. Able to give written informed consent 11. In the opinion of the investigator, willing and able to comply with required study procedures 12. Able to take oral medications (no malabsorptive condition)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnant or breastfeeding female patients
2. Female of child bearing potential unwilling or unable to use two methods of contraception
3. Received chemotherapy, immunotherapy or biological therapy within two weeks of enrolment. Prednisolone up to 20mg per day permitted for non-myeloma indications.
4. Patients with a history of another malignancy within 2 years of the baseline visit, excluding treated non-melanotic skin cancer and in-situ carcinoma.
5. Patients with known CNS involvement unless previously treated and well controlled for a period of =3 months AND which do not require the use of steroids.
6. Uncontrolled intercurrent illness including, but not limited to:
* Active or uncontrolled infection, including active HIV or viral (A, B or C) hepatitis. NOTE: Patients with controlled infection on antibiotic or antifungal therapy are eligible i.e. the patient should be afebrile for at least 72 hours and be haemodynamically stable.
* Impaired cardiac function, including any of the following:
* Myocardial infarction within previous 3 months prior to starting study
* Symptomatic congestive heart failure (New York Heart Association Class III, IV)
* Symptomatic coronary artery disease
* Cardiac arrhythmia not controlled by medication
* Clinically significant resting bradycardia (<50 beats per minute)
* Long QT syndrome or a known family history of long QT syndrome or QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
* Inability to monitor the QT/QTc interval on ECG
* Other clinically significant uncontrolled heart disease (e.g. unstable angina or uncontrolled hypertension)
* Impaired hepatic or renal impairment (see inclusion criteria)
* Uncontrolled diarrhoea, nausea or vomiting
7. concomitant exposure to another investigational agent
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/08/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
7/10/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3002 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Peter MacCallum Cancer Centre, Australia
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Melbourne Health
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will evaluate if the N-methyl-pyrrolidone (NMP) can be safely administered to humans at doses, which induce measurable immunological and anti-tumour effects in patients with myeloma who are resistant to or intolerant of lenalidomide and bortezomib.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02468687
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
David Ritchie, Prof
Query!
Address
0
0
Melbourne Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02468687
Download to PDF